Somewhat Positive Press Coverage Somewhat Unlikely to Affect Inovalon Holdings (INOV) Share Price

Headlines about Inovalon Holdings (NASDAQ:INOV) have trended somewhat positive recently, Accern Sentiment reports. The research group scores the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Inovalon Holdings earned a daily sentiment score of 0.17 on Accern’s scale. Accern also assigned press coverage about the technology company an impact score of 47.7881249282793 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Shares of Inovalon Holdings (NASDAQ INOV) traded up 0.77% during mid-day trading on Friday, reaching $13.10. 111,100 shares of the company’s stock traded hands. Inovalon Holdings has a 12-month low of $8.60 and a 12-month high of $16.64. The stock has a 50-day moving average price of $13.09 and a 200 day moving average price of $12.64. The firm has a market capitalization of $1.91 billion, a price-to-earnings ratio of 110.08 and a beta of 1.19.

Inovalon Holdings (NASDAQ:INOV) last issued its quarterly earnings results on Wednesday, August 2nd. The technology company reported $0.08 EPS for the quarter, beating the consensus estimate of $0.07 by $0.01. The company had revenue of $110.60 million for the quarter, compared to the consensus estimate of $108.73 million. Inovalon Holdings had a net margin of 4.13% and a return on equity of 5.17%. The firm’s revenue was down 10.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.14 EPS. Analysts anticipate that Inovalon Holdings will post $0.31 EPS for the current fiscal year.

A number of research firms have recently weighed in on INOV. Zacks Investment Research lowered shares of Inovalon Holdings from a “buy” rating to a “hold” rating in a report on Friday, May 5th. BidaskClub lowered shares of Inovalon Holdings from a “buy” rating to a “hold” rating in a report on Friday, August 11th. Finally, Robert W. Baird reiterated a “neutral” rating and set a $12.00 target price (up from $11.00) on shares of Inovalon Holdings in a report on Friday, June 16th. Two analysts have rated the stock with a sell rating, five have given a hold rating and two have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $14.20.

ILLEGAL ACTIVITY NOTICE: “Somewhat Positive Press Coverage Somewhat Unlikely to Affect Inovalon Holdings (INOV) Share Price” was published by Community Financial News and is owned by of Community Financial News. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark law. The correct version of this news story can be viewed at https://www.com-unik.info/2017/08/18/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-inovalon-holdings-inov-share-price.html.

In other Inovalon Holdings news, insider Shauna L. Vernal sold 19,332 shares of the company’s stock in a transaction dated Wednesday, May 24th. The shares were sold at an average price of $13.60, for a total value of $262,915.20. Following the transaction, the insider now directly owns 66,261 shares in the company, valued at approximately $901,149.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 48.28% of the stock is owned by corporate insiders.

About Inovalon Holdings

Inovalon Holdings, Inc (Inovalon) is a technology company. The Company provides cloud-based platforms empowering a data-driven transformation from volume-based to value-based models to the healthcare industry. Leveraging large-scale data interconnectivity capabilities, unparalleled proprietary data sets, advanced analytics, data-driven intervention systems, and subject matter expertise, Inovalon enables the assessment and improvement of clinical and quality outcomes and financial performance across the healthcare ecosystem.

Insider Buying and Selling by Quarter for Inovalon Holdings (NASDAQ:INOV)

What are top analysts saying about Inovalon Holdings Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Inovalon Holdings Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit